FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer

The FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Efficacy was evaluated in ADRIATIC (ClinicalTrials.gov. Identifier: NCT03703297), a randomized, double-blind, placebo-controlled trial in 730 patients with LS-SCLC whose disease had not progressed after concurrent platinum-based chemotherapy and radiation therapy. Patients were